Rare Diseases
Page 4 • 12 itemsGain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
EMA Updated Guidelines 2026: Conditional Marketing Authorizations & Accelerated Assessments
Explore the EMA's 2026 updated guidelines on Conditional Marketing Authorizations and Accelerated Assessments, enhancing drug approval processes for urgent medical needs.
Pediatric Clinical Trials EU: Impact of Revised Pediatric Investigation Plan
This article examines how the revised Pediatric Investigation Plan influences pediatric clinical trials in the EU, focusing on drug XYZ for childhood asthma.
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
AIM ImmunoTech plans Phase 3 trial for Ampligen in pancreatic cancer, backed by positive Phase 2 data and orphan drug designations in US and Europe.
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
AB Science obtains €25M clinical trial insurance for masitinib ALS Phase III study while implementing temporary European trial halt amid regulatory review.
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
MeiraGTx acquired botaretigene sparoparvovec from J&J to treat X-linked retinitis pigmentosa, planning immediate global regulatory filings for approval.
IMVT-1402 and 7 Other Late-Stage Drugs Transform Generalized Myasthenia Gravis Treatment Pipeline in 2026
Eight promising late-stage drugs including IMVT-1402 from Immunovant signal breakthrough era for generalized myasthenia gravis patients with novel mechanisms.
AI Drug Discovery EU: Accelerating Rare Disease Therapies via COMP & EMA
Discover how AI technology is transforming drug discovery for rare diseases, enhancing the development of therapies under the EU's COMP and EMA frameworks.
CHMP Positive Opinion Immunotherapy: Expanded Use in Advanced Lung Cancer
The CHMP's positive opinion on [Drug Name] marks a significant step towards expanded immunotherapy options for patients with advanced lung cancer.
EU Clinical Trials Regulation 2026: Impact on Rare Disease Drug Development
The EU Clinical Trials Regulation 2026 aims to streamline processes, significantly influencing the development of drugs for rare diseases such as Duchenne Muscular Dystrophy.
EMA Accelerated Assessment: Evaluating Rare Disease Therapies in 2026
In 2026, the EMA's Accelerated Assessment program aims to expedite the evaluation of therapies for rare diseases, enhancing patient access to treatments.
Orphan Drug Pricing EU: Market Analysis and Reimbursement Trends
This article analyzes orphan drug pricing in the EU, examining market dynamics and reimbursement trends for treatments like Spinraza in rare diseases.
EU Pharmaceutical Legislation Reform: Impact on Market Access & Innovation
The EU Pharmaceutical Legislation Reform aims to enhance market access and foster innovation, significantly affecting drug availability and patient care.